WJ-13404

N/A

Report date: 2026/05/12 20:00:17
NMEFirst In Class

Base Information

Drug NameWJ-13404
Drug Alias NameWJ-13404JS-113WJ-004
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR 19del inhibitorsEGFR T790M inhibitorsEGFR C797S inhibitors +[6] 
TargetsEpidermal growth factor receptor erbB1EGFR 19delEGFR T790M +[6] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesWigen Biomedicine technology (Shanghai) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesSuzhou Junjing Biomedical Technology Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A